Vault-13

Fairmount Funds Management LLC

WEST CONSHOHOCKEN, PA · CIK 1802528 · 13F filing filed 2022-08-15

SEC-registered investment adviser since 2019 · limited liability company

As an employer

Where they work

people there (dot area)number not reportedmain officeHover or tap a dot. Australian and UK companies are placed at their business or registered address, with their staff across the whole country.

Offices

From Form ADV: the main office and the other offices where it does advisory work (at most the 25 largest), with the people doing investment work at each. “About” is worked out: the firm's investment staff less its other offices. Each city links to the other managers there.

CityCountryPeople
West Conshohocken, PA (main office)United States United Statesabout 12
New York, NYUnited States United States
Philadelphia, PAUnited States United States

Map: places from GeoNames (CC BY 4.0), outlines from Natural Earth.

$436.9m reported value +3.3% vs Q1 2022
27positions
66.9%in top 10
6 new 6 added 6 reduced 1 sold out vs Q1 2022

Holdings, Q2 2022

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 BIOHAVEN PHARMACTL HLDG CO L COM BHVN BHVN 264,206 $38.5m8.81% 8.81% AddedShares held: Q3 2021 0, Q4 2021 55.6k, Q1 2022 239.3k, Q2 2022 264.2k +24.9k +24,892 10.4%
2 AXSOME THERAPEUTICS INC COM AXSM AXSM 942,571 $36.1m8.26% 8.26% UnchangedShares held: Q3 2021 187.6k, Q4 2021 187.6k, Q1 2022 942.6k, Q2 2022 942.6k
3 BIOCRYST PHARMACEUTICALS INC COM BCRX BCRX 3,343,107 $35.4m8.10% 8.10% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 3.3m
4 GLOBAL BLOOD THERAPEUTICS IN COM GBT GBT 953,396 $30.5m6.97% 6.97% ReducedShares held: Q3 2021 250.0k, Q4 2021 743.0k, Q1 2022 1.2m, Q2 2022 953.4k -228.9k -228,911 -19.4%
5 ARGENX SE SPONSORED ADR ARGX ARGX 73,526 $27.9m6.38% 6.38% ReducedShares held: Q3 2021 58.6k, Q4 2021 78.6k, Q1 2022 124.2k, Q2 2022 73.5k -50.7k -50,718 -40.8%
6 NEUROCRINE BIOSCIENCES INC COM NBIX NBIX 283,000 $27.6m6.31% 6.31% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 283.0k
7 INSMED INC COM PAR $.01 INSM INSM 1,326,368 $26.2m5.99% 5.99% ReducedShares held: Q3 2021 1.3m, Q4 2021 1.3m, Q1 2022 1.9m, Q2 2022 1.3m -622.4k -622,416 -31.9%
8 COGENT BIOSCIENCES INC COM COGT COGT 2,758,975 $24.9m5.70% 5.70% AddedShares held: Q3 2021 1.6m, Q4 2021 1.6m, Q1 2022 1.6m, Q2 2022 2.8m +1.2m +1,200,000 77.0%
9 NUVALENT INC COM COM 1,715,518 $23.3m5.32% 5.32% AddedShares held: Q3 2021 914.6k, Q4 2021 914.6k, Q1 2022 1.3m, Q2 2022 1.7m +377.1k +377,125 28.2%
10 ENANTA PHARMACEUTICALS INC COM ENTA ENTA 469,264 $22.2m5.08% 5.08% UnchangedShares held: Q3 2021 317.0k, Q4 2021 387.4k, Q1 2022 469.3k, Q2 2022 469.3k
11 BEIGENE LTD SPONSORED ADR ONC ONC 111,400 $18.0m4.13% 4.13% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 111.4k
12 CTI BIOPHARMA CORP COM COM 2,245,891 $13.4m3.07% 3.07% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 2.2m
13 POINT BIOPHARMA GLOBAL INC COM COM 1,833,950 $12.5m2.86% 2.86% ReducedShares held: Q3 2021 1.1m, Q4 2021 1.5m, Q1 2022 2.3m, Q2 2022 1.8m -478.6k -478,573 -20.7%
14 DBV TECHNOLOGIES S A SPONSORED ADR SPONSORED ADR 4,831,155 $12.3m2.82% 2.82% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 4.8m
15 VIRIDIAN THERAPEUTICS INC COM VRDN VRDN 944,092 $10.9m2.50% 2.50% UnchangedShares held: Q3 2021 944.1k, Q4 2021 944.1k, Q1 2022 944.1k, Q2 2022 944.1k
16 ANNEXON INC COM ANNX ANNX 2,892,600 $10.9m2.50% 2.50% AddedShares held: Q3 2021 0, Q4 2021 0, Q1 2022 1.2m, Q2 2022 2.9m +1.6m +1,643,457 131.6%
17 OLEMA PHARMACEUTICALS INC COM OLMA OLMA 2,669,300 $10.9m2.49% 2.49% UnchangedShares held: Q3 2021 0, Q4 2021 0, Q1 2022 2.7m, Q2 2022 2.7m
18 ACADIA PHARMACEUTICALS INC COM ACAD ACAD 751,804 $10.6m2.42% 2.42% ReducedShares held: Q3 2021 416.8k, Q4 2021 416.8k, Q1 2022 1.2m, Q2 2022 751.8k -405.0k -405,013 -35.0%
19 TYRA BIOSCIENCES INC COM TYRA TYRA 1,416,998 $10.1m2.32% 2.32% AddedShares held: Q3 2021 499.0k, Q4 2021 645.3k, Q1 2022 1.3m, Q2 2022 1.4m +132.0k +132,008 10.3%
20 AMARIN CORP PLC SPONS ADR NEW SPONS ADR NEW 5,584,837 $8.3m1.90% 1.90% AddedShares held: Q3 2021 2.5m, Q4 2021 2.5m, Q1 2022 4.1m, Q2 2022 5.6m +1.5m +1,451,600 35.1%
21 KEROS THERAPEUTICS INC COM KROS KROS 272,498 $7.5m1.72% 1.72% ReducedShares held: Q3 2021 149.3k, Q4 2021 292.8k, Q1 2022 396.9k, Q2 2022 272.5k -124.4k -124,413 -31.4%
22 TREVI THERAPEUTICS INC COM TRVI TRVI 1,624,389 $4.6m1.04% 1.04% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 1.6m
23 IOVANCE BIOTHERAPEUTICS INC COM IOVA IOVA 389,588 $4.3m0.98% 0.98% UnchangedShares held: Q3 2021 389.6k, Q4 2021 389.6k, Q1 2022 389.6k, Q2 2022 389.6k
24 VERONA PHARMA PLC SPONSORED ADS VRNA VRNA 926,602 $3.9m0.89% 0.89% UnchangedShares held: Q3 2021 926.6k, Q4 2021 926.6k, Q1 2022 926.6k, Q2 2022 926.6k
25 INSTIL BIO INC COM COM 673,905 $3.1m0.71% 0.71% UnchangedShares held: Q3 2021 673.9k, Q4 2021 673.9k, Q1 2022 673.9k, Q2 2022 673.9k
26 ASTRIA THERAPEUTICS INC COM CATB CATB 911,736 $2.7m0.63% 0.63% UnchangedShares held: Q3 2021 911.7k, Q4 2021 911.7k, Q1 2022 911.7k, Q2 2022 911.7k
27 ALLAKOS INC COM ALLKG ALLKG 147,189 $461.0k0.11% 0.11% UnchangedShares held: Q3 2021 175.4k, Q4 2021 147.2k, Q1 2022 147.2k, Q2 2022 147.2k

Sold out since Q1 2022

SecurityTickerShares held beforeValue then
PROTAGONIST THERAPEUTICS INC PTGX PTGX 549,988 $13.0m550.0k shares

Stakes above 5%

Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.

CompanyTickerStakeChange ScheduleLast filed
ALAUNOS THERAPEUTICS INC TCRT · 13D · filed 2026-10-15 TCRT 20.0%≈ $1.3m new 13D 2026-10-15
JADE BIOSCIENCES INC JBIO · 13D · filed 2026-06-09 JBIO 20.0%≈ $310.7m no change 13D 2026-06-09
DAMORA THERAPEUTICS INC 13D · filed 2026-02-11 20.0%≈ $226.6m no change 13D 2026-02-11
ORUKA THERAPEUTICS INC ORKA · 13D · filed 2026-07-01 ORKA 19.5%≈ $1.4bn -0.5 pts 13D 2026-07-01
CRESCENT BIOPHARMA INC. CBIO · 13D · filed 2026-07-20 CBIO 16.5%≈ $118.8m -2.0 pts 13D 2026-07-20
VIRIDIAN THERAPEUTICS INC VRDN · 13D · filed 2026-05-13 VRDN 14.0%≈ $316.0m -1.1 pts 13D 2026-05-13
SPYRE THERAPEUTICS INC SYRE · 13D · filed 2026-10-09 SYRE 10.0%≈ $860.2m no change 13D 2026-10-09
INHIBIKASE THERAPEUTICS INC IKT · 13G · filed 2026-02-17 IKT 9.9%≈ $25.3m no change 13G 2026-02-17
COGENT BIOSCIENCES INC COGT · 13D · filed 2026-03-31 COGT 8.6%≈ $594.3m -1.3 pts 13D 2026-03-31

Trades reported as a company insider in Q2 2022

Owning 10% or more of a company, or having someone on its board, makes this manager an insider there: it reports its trades in that company's shares on Form 4 within two business days. Open-market and private purchases and sales only.

DateCompanyTickerTradeShares ValueTheir holding
2022-06-16 COGENT BIOSCIENCES INC 10% owner · Fairmount Healthcare Fund II LP COGT Bought 1,200,000 $9.9m1.2m shares +94%